Merck Undeterred By Upcoming Singulair Loss; Focuses On Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck reports second quarter earnings, looking past the patent expiration of Singulair to the drugs it icurrently is developing to replace the revenues it is expected to lose.